<DOC>
	<DOCNO>NCT01068860</DOCNO>
	<brief_summary>This 10-week , placebo-controlled , randomize study investigate effect injectable IL-1B antagonist , Canakinumab , participant impair glucose tolerance Type 2 Diabetes Mellitus ( T2DM ) already treat different background diabetes therapy .</brief_summary>
	<brief_title>To Compare Effect Subcutaneous Canakinumab Administration Placebo Patients With Impaired Glucose Tolerance Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Troglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<mesh_term>Acetohexamide</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patient must fulfill criteria one follow group : Impaired Glucose Tolerance ( IGT ) diagnose per protocol antidiabetic medicine study Diagnosis Type 2 diabetes stable treatment metformin Diagnosis Type 2 diabetes stable treatment metformin ( least 1000 mg/day ) combination sulfonylurea Diagnosis Type 2 diabetes stable treatment metformin ( least 1000 mg/day ) , sulfonylurea thiazolidinedione combination therapy Diagnosis Type 2 diabetes stable treatment least two insulin injection day without metformin 2 . HbA1c 6.5 % 8 % , inclusive , Screening ; criterion apply IGT group 3 . Age 1874 year , inclusive , either sex 1 . Type 1 diabetes diabetes result pancreatic injury secondary form diabetes 2 . History current finding active pulmonary disease ( e.g . tuberculosis , fungal disease ) define protocol : 3 . Known presence suspicion active recurrent bacterial , fungal viral infection time enrollment proven .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>canakinumab</keyword>
	<keyword>Pre diabetic</keyword>
	<keyword>glucose intolerant</keyword>
	<keyword>oral anti diabetic medication</keyword>
	<keyword>insulin treatment</keyword>
	<keyword>metabolic syndrome</keyword>
</DOC>